Bradley Pharmaceuticals Anticipates Significant Sales Increases for Lubrin Vaginal Moisturizer as a Result of the Popularity of Viagra.

FAIRFIELD, N.J.--(BUSINESS WIRE)--May 7, 1998--BRADLEY PHARMACEUTICALS, INC. (NASDAQ NM: BPRX) foresees male Viagra(R) (Registered trademark of Pfizer, Inc. NYSE: PFE) patients increased sexual drive significantly affecting female usage of Lubrin(R) Vaginal Lubricant inserts. It is estimated in excess of 20 million post-menopausal women currently suffer from vaginal dryness.

Many health-care experts share the view of Karin Martin, Sex Therapist at Hillside Hospital's Sexuality Center in Lake Success, New York, who spoke about male patients in their mid 40's through 60's taking Viagra(R) and "their partners are happy they are able to have a more complete sexual relationship." Many other experts including Glenda Carle, author of "Don't Bet on the Prince!", state that a number of women who have gone through menopause may have to use additional vaginal lubricants.

Bradley Pharmaceuticals' reports increased sales for Lubrin(R) since the introduction of Viagra(R) and expects sales to increase more with increased sexual activity among middle-aged Viagra(R) users and their partners.

Lubrin(R) is a leading vaginal lubricant specifically designed to provide fast and prolonged lubrication for vaginal dryness. It has been recommended for years by Obstetricians and Gynecologists as a proven, safe and reliable form of personal lubrication which is odorless, colorless and non-staining. Lubrin(R) which simulates the body's natural lubrication, is designed to be the most convenient, non-messy vaginal lubricant available.

Lubrin(R), available without a prescription, is distributed nationally and available in independent pharmacies as well as pharmacy chains such as: Walgreens, CVS and Eckerds.

BRADLEY PHARMACEUTICALS, INC. manufactures and markets brandname products and over-the-counter pharmaceuticals and health-related products throughout the United States as well as in twenty-six international markets.

This release may contain forward-looking statements which reflect management's current views of future events and operations. These forward-looking statements are based on assumptions and external factors, including assumptions relating to regulatory action, capital requirements and competing products. Any changes in such assumptions are external factors and could produce significantly different results.

CONTACT: Bradley Pharmaceuticals, Inc.

Daniel Glassman

Chairman and CEO 

973/882-1505, Ext. 210

or

DeMonte Associates

Cynthia DeMonte

212/473-3700

e-mail: [e-mail]